Shanghai Junshi Biosciences Co., Ltd. announced that Suzhou Junjing Biomedical Technology Co., Ltd., a company jointly invested by Junshi Biosciences and Wigen Biomedicine Technology (Shanghai) Co., Ltd., has received a notice from the U.S. Food and Drug Administration (the "FDA") concerning the approval of the investigational new drug ("IND") application for XPO1 inhibitor WJ01024 tablets (product code: "JS110") by the FDA.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.62 HKD | 0.00% | +2.27% | -35.08% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-35.08% | 3.56B | |
-2.35% | 89.08B | |
+2.76% | 40.9B | |
-13.46% | 32.25B | |
+54.69% | 25.14B | |
-16.02% | 15.39B | |
-9.08% | 11.91B | |
-42.60% | 11.89B | |
-12.82% | 11.64B | |
+7.34% | 9.03B |
- Stock Market
- Equities
- 1877 Stock
- News Shanghai Junshi Biosciences Co., Ltd.
- Suzhou Junjing Biomedical Technology Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)